{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:14:21Z","timestamp":1791389661848,"version":"4.3.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T00:00:00Z","timestamp":1511481600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s10620-017-4850-1","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T07:35:14Z","timestamp":1511508914000},"page":"61-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network"],"prefix":"10.1007","volume":"63","author":[{"given":"Ye Eun","family":"Kwak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,24]]},"reference":[{"key":"4850_CR1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.28109","volume":"63","author":"H Roberts","year":"2016","unstructured":"Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988\u20132012. Hepatology. 2016;63:388\u2013397.","journal-title":"Hepatology"},{"key":"4850_CR2","first-page":"370","volume":"10","author":"HI Kawsar","year":"2012","unstructured":"Kawsar HI, Shahnewaz J, Gopalakrishna KV, Spiro TP, Daw HA. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis. Clin Adv Hematol Oncol. 2012;10:370\u2013378.","journal-title":"Clin Adv Hematol Oncol"},{"key":"4850_CR3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221\u2013244.","journal-title":"Gastroenterology"},{"key":"4850_CR4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","volume":"9","author":"HA Torres","year":"2012","unstructured":"Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156\u2013166.","journal-title":"Nat Rev Clin Oncol"},{"key":"4850_CR5","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156\u2013S165.","journal-title":"Hepatology"},{"key":"4850_CR6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","volume":"33","author":"D Shouval","year":"2013","unstructured":"Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33:167\u2013177.","journal-title":"Semin Liver Dis"},{"key":"4850_CR7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519\u2013528.","journal-title":"Ann Intern Med"},{"key":"4850_CR8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","volume":"47","author":"C Hsu","year":"2008","unstructured":"Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin\u2019s lymphoma: a randomized trial. Hepatology. 2008;47:844\u2013853.","journal-title":"Hepatology"},{"key":"4850_CR9","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","volume":"125","author":"GK Lau","year":"2003","unstructured":"Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742\u20131749.","journal-title":"Gastroenterology"},{"key":"4850_CR10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","volume":"164","author":"S Paul","year":"2016","unstructured":"Paul S, Saxena A, Terrin N, et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30\u201340.","journal-title":"Ann Intern Med."},{"key":"4850_CR11","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/annonc\/mdw414","volume":"27","author":"CS Voican","year":"2016","unstructured":"Voican CS, Mir O, Loulergue P, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol. 2016;27:2172\u20132218.","journal-title":"Ann Oncol"},{"key":"4850_CR12","unstructured":"US Food and Drug Administration. Boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). Drug Safety Communications. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM369436.pdf. Published September 25, 2013."},{"key":"4850_CR13","first-page":"1","volume":"57","author":"CM Weinbaum","year":"2008","unstructured":"Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1\u201320.","journal-title":"MMWR Recomm Rep"},{"key":"4850_CR14","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","volume":"33","author":"JP Hwang","year":"2015","unstructured":"Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol. 2015;33:2212\u20132220.","journal-title":"J Clin Oncol"},{"key":"4850_CR15","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","volume":"28","author":"A Artz","year":"2010","unstructured":"Artz A, Somerfield M, Feld J, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010;28:3199\u20133202.","journal-title":"J Clin Oncol"},{"key":"4850_CR16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215\u2013219.","journal-title":"Gastroenterology"},{"key":"4850_CR17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661\u2013662.","journal-title":"Hepatology"},{"key":"4850_CR18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/1471-2407-13-534","volume":"13","author":"JP Hwang","year":"2013","unstructured":"Hwang JP, Fisch MJ, Lok AS, et al. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer. 2013;13:534.","journal-title":"BMC Cancer"},{"key":"4850_CR19","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s10620-016-4118-1","volume":"61","author":"S Paul","year":"2016","unstructured":"Paul S, Shuja A, Tam I, et al. Gastroenterologists have suboptimal hepatitis B virus screening rates in patients receiving immunosuppressive therapy. Dig Dis Sci. 2016;61:2236\u20132241.","journal-title":"Dig Dis Sci"},{"key":"4850_CR20","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.30381","volume":"123","author":"K Junus","year":"2017","unstructured":"Junus K, Aguilar M, Patel P, et al. Improvements in hepatitis B virus screening before rituximab therapy: a community-based, safety-net hospital experience. Cancer. 2017;123:650\u2013656.","journal-title":"Cancer"},{"key":"4850_CR21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12072-015-9692-3","volume":"10","author":"KS Cheung","year":"2016","unstructured":"Cheung KS, Seto WK, Lai CL, et al. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int. 2016;10:407\u2013414.","journal-title":"Hepatol Int"},{"key":"4850_CR22","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.cgh.2014.10.032","volume":"13","author":"CI Wi","year":"2015","unstructured":"Wi CI, Loo NM, Larson JJ, et al. Low level of hepatitis B virus screening among patients receiving chemotherapy. Clin Gastroenterol Hepatol. 2015;13:970\u2013975.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4850_CR23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3748\/wjg.v19.i6.923","volume":"19","author":"Y Wang","year":"2013","unstructured":"Wang Y, Luo XM, Yang D, et al. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol. 2013;19:923\u2013930.","journal-title":"World J Gastroenterol"},{"key":"4850_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3747\/co.v17i6.653","volume":"17","author":"R Lee","year":"2010","unstructured":"Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol. 2010;17:32\u201338.","journal-title":"Curr Oncol"},{"key":"4850_CR25","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s10147-016-0995-8","volume":"21","author":"M Ikeda","year":"2016","unstructured":"Ikeda M, Yamamoto H, Kaneko M, et al. Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan. Int J Clin Oncol. 2016;21:1162\u20131166.","journal-title":"Int J Clin Oncol"},{"key":"4850_CR26","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.3748\/wjg.v22.i19.4732","volume":"22","author":"CM Hunt","year":"2016","unstructured":"Hunt CM, Beste LA, Lowy E, et al. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. World J Gastroenterol. 2016;22:4732\u20134740.","journal-title":"World J Gastroenterol"},{"key":"4850_CR27","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1200\/JOP.2011.000450","volume":"8","author":"JP Hwang","year":"2012","unstructured":"Hwang JP, Fisch MJ, Zhang H, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012;8:e32\u2013e39.","journal-title":"J Oncol Pract"},{"key":"4850_CR28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/SMJ.0b013e318238b608","volume":"104","author":"JG Stine","year":"2011","unstructured":"Stine JG, Bass M, Ibrahim D, Khokhar OS, Lewis JH. Dermatologists\u2019 awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-alpha inhibitor therapy. South Med J. 2011;104:781\u2013788.","journal-title":"South Med J"},{"key":"4850_CR29","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/acr.20209","volume":"62","author":"JG Stine","year":"2010","unstructured":"Stine JG, Khokhar OS, Charalambopoulos J, Shanmugam VK, Lewis JH. Rheumatologists\u2019 awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res. 2010;62:704\u2013711.","journal-title":"Arthritis Care Res"},{"key":"4850_CR30","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/MEG.0000000000000689","volume":"28","author":"JK Dyson","year":"2016","unstructured":"Dyson JK, Jopson L, Ng S, et al. Improving testing for hepatitis B before treatment with rituximab. Eur J Gastroenterol Hepatol. 2016;28:1172\u20131178.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-017-4850-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4850-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4850-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T08:15:46Z","timestamp":1659946546000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-017-4850-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["4850"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4850-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,24]]}}}